Immunotherapies are revolutionizing cancer treatment outcomes.
Yet, there is something missing:
A personalized, comprehensive analysis of how each person's cancer is escaping immune system control.
This could help patients know from which immunotherapy treatments and clinical trials they might benefit most.
We intend to be a driving force to build this missing piece into clinical practice, beginning with tumor MHC I analysis.
This is our starting point.
Please join us.
Education
We provide weekly updates to patients and physicians about the most recently launched immunotherapy clinical trials for solid tumors. These updates include details about the trial, but more importantly how the trial drug is designed to work along with available documentation of benefit. Sign up for these weekly updates on our subscribe page.
We are also creating a world-class video series to effortlessly educate people from all backgrounds about the immune system, cancer immunotherapies and clinical trials.
Decentralized Clinical Trials
Immune system cells are suppressed in the microenvironment of a tumor in a myriad of ways.
Some of these immunosuppressive mechanisms can be altered with readily available, low cost therapeutics.
We intend to fund decentralized clinical trials testing these substances in combinations as a general platform for improving immunotherapy outcomes.
ENVISIONING A WORLD WHERE ALL CANCER IS CURABLE
We intend to transform the way cancer immunotherapy trials are designed over the long-term so that the patient is at the center of the trial and the goal is to bring about cures faster.
It will mean big changes in the way things are done both by pharma and the FDA, but we believe the changemakers will have the imagination and vision to join us in this endeavor.